natgillin/translations-raw huggingface dataset:
Tell your doctor if you or your partner become pregnant or plan to become pregnant while you are being treated with COMETRIQ. 
Zdravniku povejte, če vi ali vaša partnerica zanosite ali načrtujete zanositev med zdravljenjem z zdravilom COMETRIQ.
Cabozantinib has shown no mutagenic or clastogenic potential in a standard battery of genotoxicity assays. 
Kabozantinib ni kazal mutagenega ali klastogenega potenciala v standardnemu nizu genotoksičnih testov.
Therapy with COMETRIQ should be initiated by a physician experienced in the administration of anticancer medicinal products. 
Zdravljenje z zdravilom COMETRIQ mora uvesti zdravnik z izkušnjami v uporabi zdravil za zdravljenje raka.
Cabozantinib should be restarted with a lower dose when PPES has been resolved to grade 1. 
Nadaljevanje zdravljenja s kabozantinibom naj se začne z nižjim odmerkom, ko se PPES umiri do 1. stopnje.
4.0 months 
4,0 meseci
Palmar-plantar erythrodysaesthesia syndrome 
Sindrom palmarno-plantarne eritrodisestezije
COMETRIQ may slow or stop the growth of medullary thyroid cancer. 
Zdravilo COMETRIQ lahko upočasni ali ustavi rast medularnega raka ščitnice.
Each blister card has enough capsules to last for seven days (one week). 
Vsaka pretisna zgibanka vsebuje dovolj kapsul za vsaj sedem dni (en teden).
Each day, take all the capsules across the row. 
Vsak dan vzemite vse kapsule v eni vrsti.
Figure 3: Kaplan-Meier Analysis of OS Among Subjects with a RET M918T Mutation 
Slika 3: Kaplan-Meierjeva analiza OS pri osebah z mutacijo RET M918T
In vitro data demonstrate that cabozantinib is a substrate of MRP2. 
Podatki in vitro kažejo, da je kabozantinib substrat MRP2.
This could mean that your doctor needs to change the dose(s) that you take. 
To pomeni, da bo morda zdravnik moral prilagoditi odmerek/odmerke, ki jih jemljete.
• Hypertension (increase in blood pressure) 
• hipertenzija (zvišanje krvnega tlaka)
Effect of other medicinal products on cabozantinib 
Učinek drugih zdravil na kabozantinib
The median duration of objective responses was 14.6 months (95% CI: 11.1, 17.5) for subjects in the cabozantinib arm. 
Mediana trajanja objektivnega odgovora je bila 14,6 mesecev (95-% IZ: 11,1; 17,5) za osebe v kraku s kabozantinibom.
This is because COMETRIQ can affect the way some other medicines work. 
To je pomembno, ker lahko zdravilo COMETRIQ vpliva na način delovanja nekaterih zdravil.
Cabozantinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs) implicated in tumour growth and angiogenesis, pathologic bone remodeling, and metastatic progression of cancer. 
Kabozantinib je majhna molekula, ki zavira več receptorskih tirozin-kinaz (RTK), ki so vpletene v rast tumorja in angiogenezo, patološko preoblikovanje kosti in metastatsko napredovanje raka.
COMETRIQ is indicated for the treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma. 
Zdravilo COMETRIQ je indicirano za zdravljenje odraslih bolnikov s progresivnim, neizrezljivim, lokalno napredovalim ali metastatskim medularnim karcinomom ščitnice.
Findings in uterus/ovaries and decreased haematopoiesis appeared to be transient, while effects on bone parameters and liver pigmentation were sustained. 
Kaže, da so izsledki v maternici/jajčnikih in zmanjšana hematopoeza prehodni, medtem ko učinki na kostne parametre in pigmentacijo jeter ostali.
Use caution when driving or using machines. 
Med vožnjo ali uporabo strojev bodite previdni.
Overall Response Ratea (95% CI) 
Splošna stopnja odzivaa (95-% IZ)
Cabozantinib is a CYP3A4 substrate. 
Kabozantinib je substrat CYP3A4.
Close monitoring of patients is therefore recommended during the first eight weeks of therapy (see section 4.2). 
Zato se v prvih osmih tednih zdravljenja priporoča skrbno opazovanje bolnikov (glejte poglavje 4.2).
Median Overall Survival 
Mediano celokupno preživetje
Also, some medicines can affect the way COMETRIQ works. 
Prav tako lahko tudi nekatera zdravila vplivajo na delovanje zdravila COMETRIQ.
You may need treatment for them, or your doctor may decide to change your dose of COMETRIQ, or stop treatment altogether. 
Morda vas bo treba zdraviti ali pa se bo zdravnik odločil, da spremeni odmerek zdravila COMETRIQ ali zdravljenje ukine.
Talk to your doctor about which methods of contraception are appropriate while you are taking COMETRIQ. 
S svojim zdravnikom se posvetujte o metodah kontracepcije, ki so ustrezne med uporabo zdravila COMETRIQ.
• Weakness or reduced sensation or tingling in the limbs 
• šibkost ali zmanjšanje občutenja ali ščemenje v udih
No data are available to determine a difference in PK based on race. 
Podatki, na podlagi katerih bi bilo mogoče ugotoviti razlike v farmakokinetiki na podlagi rase, niso na voljo.
Cabozantinib was not carcinogenic in the rasH2 mouse model at a slightly higher exposure than the intended human therapeutic exposure. 
Kabozantinib v mišjem modelu rasH2 ni bil kancerogen ob nekoliko večji izpostavljenosti, kot je nameravana terapevtska izpostavljenost pri ljudeh.
• Hypotension (decrease in blood pressure) 
• hipotenzija (znižanje krvnega tlaka)
The resulting DNA samples will be evaluated for quality by a PCR-based amplification test, and by Sanger sequencing for RET M918T. 
Pridobljene vzorce DNA bodo ocenili glede kakovosti v testu pomnoževanja na podlagi PCR in z določanjem zaporedja za RET M918T z metodo po Sangerju.
• Protein or blood in the urine, gallstones, painful urination 
• beljakovine ali kri v urinu, žolčni kamni, boleče odvajanje urina
A neutralizing antibody to CYP2C9 showed a minimal effect on cabozantinib metabolite formation (ie, a <20% reduction). 
Nevtralizirajoče protitelo za CYP2C9 je pokazalo minimalni učinek na nastanek presnovka kabozantiniba (tj. zmanjšanje za < 20 %).
Mean clearance (CL/F) at steady-state in cancer patients was estimated to be 4.4 L/hr in a population PK analysis. 
Povprečni očistek (CL/F) v stanju dinamičnega ravnovesja pri bolnikih z rakom je bil v farmakokinetični analizi populacije ocenjen na 4,4 l/uro.
Disease Control Rate b (95% CI) Calcitonin Responsea 
Stopnja nadzora bolezni b (95-% IZ) Odziv na kalcitonina
Pharmacotherapeutic group: antineoplastic agent, protein kinase inhibitor, ATC code: L01XE26. 
Farmakoterapevtska skupina: zdravila z delovanjem na novotvorbe, zaviralci proteinske kinaze, oznaka ATC: L01XE26
• Swelling in the face and in other parts of the body 
• oteklost obraza in drugih delov telesa
RET mutation negative patients with no evidence of RAS mutation (n=33) showed a decreased PFS benefit on cabozantinib (HR of 0.87) and a lower response rate of 18% compared to other mutational subgroups. 
Bolniki, negativni za mutacijo RET, in brez znakov mutacije RAS (n = 33) so pokazali zmanjšano korist PFS pri uporabi kabozantiniba (HR 0,87) in z 18 % nižjo stopnjo odziva v primerjavi z drugimi mutacijskimi podskupinami.
If you have taken more COMETRIQ than you have been instructed to, talk to a doctor or go to the hospital with the capsules and this leaflet straight away. 
Če ste vzeli večji odmerek zdravila COMETRIQ, kot bi smeli Če ste vzeli več zdravila COMETRIQ, kot vam je bilo naročeno, se pogovorite z zdravnikom ali takoj pojdite v bolnišnico s kapsulami in tem navodilom.
In the case of persistent hypertension despite use of anti-hypertensives, the cabozantinib dose should be reduced. 
V primeru trdovratne hipertenzije kljub uporabi antihipertenzivov je treba odmerek kabozantiniba zmanjšati.
Tumor tissue samples initially will undergo histological evaluation, manual tumor enrichment, and DNA isolation. 
Vzorci tumorskega tkiva se bodo najprej ocenili histološko, s pomočjo ročne obogatitve tumorja in izolacije DNA.
Effect of cabozantinib on other medicinal products 
Učinek kabozantiniba na druga zdravila
Other medicines and COMETRIQ 
Druga zdravila in zdravilo COMETRIQ
In patients with mild or moderate hepatic impairment the recommended dose of cabozantinib is 60 mg once daily. 
Pri bolnikih z blago ali zmerno jetrno okvaro je priporočeni odmerek kabozantiniba 60 mg enkrat na dan.
Each row of the blister card contains the daily dose. 
Vsaka vrsta pretisne zgibanke vsebuje dnevni odmerek.
PK assessments will be required for all subjects (both dose groups). 
Za vse osebe (v skupinah z obema odmerkoma) se bo ocenila FK.
• A tear or abnormal connection of the tissue in your digestive system; symptoms can include severe or persistent stomach ache 
• raztrganje ali nenormalne povezave tkiva v prebavilih; simptomi lahko vključujejo hude ali trdovratne bolečine v trebuhu
The objective response rates measured in these subgroups were generally consistent with the PFS results, with the RET mutation positive, negative, and unknown subgroups showing tumour response rates of 32%, 22%, and 25%, respectively. 
Objektivne stopnje odzivov, izmerjene v teh podskupinah, so bile na splošno konsistentne z rezultati PFS, pri čemer so bile stopnje odziva v podskupini s pozitivno mutacijo RET 32 %, v podskupini z negativno mutacijo RET 22 % in v podskupini z neznano mutacijo RET 25 %.
What you need to know before you take COMETRIQ 3. 
Kaj morate vedeti, preden boste vzeli zdravilo COMETRIQ 3.
Patients should be instructed to not eat anything for at least 2 hours before through 1 hour after taking COMETRIQ. 
Bolnikom je treba naročiti, naj vsaj 2 uri pred uporabo zdravila COMETRIQ in 1 uro po tem ničesar ne jedo.
Avoid consuming grapefruit-containing products for as long as you are using this medicine, as it may increase the levels of COMETRIQ in your blood. 
Dokler uporabljate zdravilo COMETRIQ, ne jejte živil, ki vsebujejo grenivko, saj lahko zviša ravni zdravila v krvi.
Repeat daily dosing of cabozantinib at 140 mg for 19 days resulted in an approximately a 4- to 5-fold mean cabozantinib accumulation (based on AUC) compared to a single dose administration; steady state is achieved by approximately Day 15. 
Ponavljajoče se dnevno odmerjanje kabozantiniba v odmerku 140 mg za 19 dni je povzročilo približno 4- do 5-kratno povprečno kopičenje kabozantiniba (na podlagi AUC) v primerjavi z uporabo enega odmerka; stanje dinamičnega ravnovesja se doseže na približno 15. dan.
RPLS is uncommon (it affects less than 1 in 100 people). 
RPLS je občasen neželeni učinek (prizadene manj kot 1 od 100 bolnikov).
Cabozantinib should be discontinued if hypertension is severe and persistent despite anti-hypertensive therapy and dose reduction of cabozantinib. 
Z uporabo kabozantiniba je treba prenehati, če je hipertenzija resna ali trdovratna kljub zdravljenju z antihipertenzivi in zmanjšanjem odmerka kabozantiniba.
A dose-comparison study (XL-184-401) (140 mg vs 60 mg) in 112 patients with hereditary or sporadic medullary thyroid cancer. 
Študija primerjave odmerka (XL-184-401) (140 mg v primerjavi s 60 mg) pri 112 bolnikih z dednim ali sporadičnim medularnim rakom ščitnice.
Cabozantinib should not be used during pregnancy unless the clinical condition of the woman requires treatment with cabozantinib. 
Kabozantiniba ne smete uporabljati med nosečnostjo, razen če zdravljenje s kabozantinibom ni nujno potrebno zaradi kliničnega stanja ženske.
Monitor for adverse events and adjust dose or use dosing interruption as needed (see section 4.2). 
Spremljati je treba neželene učinke in odmerek po potrebi prilagajati ali dajanje prekiniti (glejte poglavje 4.2).
Dose interruptions are recommended for management of CTCAE grade 3 or greater toxicities or intolerable grade 2 toxicities. 
Prekinitev odmerka se priporoča pri obravnavi toksičnosti 3. ali višje stopnje po CTCAE (common terminology criteria for adverse events) ali nevzdržnih toksičnosti 2. stopnje.
E. SPECIFIC OBLIGATION TO COMPLETE POST-AUTHORISATION MEASURES FOR THE CONDITIONAL MARKETING AUTHORISATION This being a conditional marketing authorisation and pursuant to Article 14(7) of Regulation (EC) No 726/2004, the MAH shall complete, within the stated timeframe, the following measures: Description 
Ker gre za pogojno dovoljenje za promet z zdravilom in ob upoštevanju člena 14(7) Uredbe (ES) št. 726/2004, mora imetnik dovoljenja za promet z zdravilom v določenem časovnem okviru izvesti naslednje ukrepe:
Your capsules are also available as a 28 day pack, which contains enough capsules to last for 28 days, in 4 blister cards with seven days of capsules on each card. 
Kapsule so na voljo kot 28-dnevno pakiranje, ki vsebuje dovolj kapsul za 28 dni v 4 pretisnih zgibankah s kapsulami za sedem dni na vsaki zgibanki.
Fresh tumour samples for tumour genetic analysis from the most recent metastatic site in patients enrolled in the dose-comparison study should be collected. 
Odvzeti je treba sveže vzorce tumorjev za gensko analizo tumorjev na nazadnje nastalih mestih zasevkov pri bolnikih, vključenih v študijo primerjave odmerka.
Centralized, independent, blinded review of the imaging data was used in the assessment of PFS and ORR. 
Pri oceni PFS in ORR so opravili centralizirane, neodvisne, slepe preglede slikovnih podatkov.
Because of high plasma protein binding levels of cabozantinib (section 5.2) a plasma protein displacement interaction with warfarin may be possible. 
Zaradi visoke stopnje vezave kabozantiniba na plazemske beljakovine (glejte poglavje 5.2), lahko pride do interakcije izpodrivanja plazemskih beljakovin z varfarinom.
The PFS results were consistent across all baseline and demographic subgroups evaluated, including prior therapy with tyrosine kinase inhibitors (which may have consisted of agents targeting pathways associated with anti-angiogenesis), RET mutational status (including subjects documented not to have RET mutations), prior anticancer or radiotherapy status, or the existence of bone metastases. 
Rezultati PFS so bili konsistentni za vsa izhodišča in ocenjene demografske podskupine, vključno s predhodnim zdravljenjem z zaviralci tirozin-kinaze (ki je lahko zajemalo učinkovine, ki so ciljale na poti, povezane z anti-angiogenezo), statusom mutacije RET (vključno z osebami, za katere je bilo dokumentirano, da nimajo mutacij RET), predhodnim statusom zdravljenja raka ali obsevanja ali obstojem kostnih metastaz.
The capsule contains an off-white to white powder. 
Kapsula vsebuje belkast do bel prašek.
Your capsules will come in a blister card organised by prescribed dose. 
Kapsule so pakirane v pretisne zgibanke, organizirane glede na predpisani odmerek.
26.6 months 
26,6 mesecev
11.2 months 
11,2 meseca
Cabozantinib is a substrate for CYP3A4 metabolism in vitro, as a neutralizing antibody to CYP3A4 inhibited formation of metabolite XL184 N-oxide by >80% in a NADPH-catalyzed human liver microsomal (HLM) incubation; in contrast, neutralizing antibodies to CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C19, CYP2D6 and CYP2E1 had no effect on cabozantinib metabolite formation. 
Kabozantinib je in vitro substrat presnove CYP3A4, kot nevtralizirajoče protitelo za nastanek presnovka XL184 N-oksida, ki ga zavre CYP3A4 za > 80 %, v inkubaciji mikrosomov človeških jeter, kataliziranega z NADPH; nasprotno pa nevtralizirajoča protitelesa za CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C19, CYP2D6 in CYP2E1 niso vplivala na nastanek presnovka kabozantiniba.
Adverse reactions are listed in Table 1 according to MedDRA system organ class and frequency categories. 
Neželeni učinki v preglednici 1 so razvrščeni po dogovoru MedDRA po organskih sistemih in pogostnosti.
COMETRIQ capsules are packaged in blister cards organised by prescribed dose. 
COMETRIQ kapsule so pakirane v pretisne zgibanke, urejene glede na predpisani odmerek.
Within a 48-day collection period after a single dose of 14C-cabozantinib in healthy volunteers, approximately 81% of the total administered radioactivity was recovered with 54% in faeces and 27% in urine. 
V 48-dnevnem obdobju zbiranja po enem odmerku 14C-kabozantiniba pri zdravih prostovoljcih se je približno 81 % skupne uporabljene radioaktivnosti izločilo z blatom (54 %) in urinom (27 %).
Clinical data in medullary thyroid cancer 
Klinični podatki pri medularnem raku ščitnice
Patients with severe renal impairment have not been studied. 
Bolnikov s hudo okvaro ledvic niso preučevali.
• Blood clots in the arteries 
• krvni strdki v arterijah
COMETRIQ is a medicine used to treat medullary thyroid cancer, a rare type of thyroid cancer, that cannot be removed by surgery or that has spread to other parts of the body. 
Kaj je zdravilo COMETRIQ in za kaj ga uporabljamo Zdravilo COMETRIQ se uporablja za zdravljenje medularnega raka ščitnice, ki je redka vrsta raka ščitnice in se ga ne da kirurško odstraniti ali pa se je razširil na druge dele telesa.
Urine protein should be monitored regularly during cabozantinib treatment. 
V času zdravljenja s kabozantinibom je treba redno spremljati beljakovine v urinu.
OTHER SPECIAL WARNING(S), IF NECESSARY Refer to individual blister cards for dispensing instructions. 
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA Za navodila glede dajanja glejte posamezne pretisne zgibanke.
Following oral administration of cabozantinib, peak cabozantinib plasma concentrations are reached at 2 to 5 hours post-dose. 
Po peroralni uporabi kabozantiniba so najvišje koncentracije kabozantiniba v plazmi dosežene 2 do 5 ur po odmerku.
Four metabolites were present in plasma at exposures (AUC) greater than 10% of parent: XL184-N-oxide, XL184 amide cleavage product, XL184 monohydroxy sulfate, and 6-desmethyl amide cleavage product sulfate. 
V plazmi so bili prisotni štirje presnovki z izpostavljenostmi (AUC), večjimi kot 10 % izhodiščne spojine: XL184-N-oksid, produkt cepitve XL184 amida, XL184 monohidroksi sulfat in produkt cepitve 6-desmetil amida sulfat.
Of the 215 subjects with sufficient data to determine mutational status, 78.6% (n=169) were classified as RET mutation positive (126 of which were positive for the M918T mutation), and 21.4% (n=46) were classified as RET mutation negative. 
Med 215 osebami, pri katerih so podatki zadoščali za določitev statusa mutacije, jih je bilo 78,6 % (n = 169) razvrščenih kot pozitivnih za mutacijo RET (126 med njimi je bilo pozitivnih za mutacijo M918T) in 21,4 % (n = 46) je bilo razvrščenih kot negativnih za mutacijo RET. Za dodatnih 115 oseb statusa mutacije RET ni bilo mogoče določiti ali ni bil jasen.
Cabozantinib treatment should be stopped at least 28 days prior to scheduled surgery, if possible. 
Zdravljenje s kabozantinibom je treba ustaviti vsaj 28 dni pred načrtovanim operativnim posegom, če je mogoče.
You should also use a barrier contraceptive (e.g. condom or diaphragm) whilst taking COMETRIQ and for at least 4 months after treatment has finished. 
Zato morate med jemanjem zdravila COMETRIQ in še vsaj 4 mesece po koncu zdravljenja uporabljati tudi pregradno kontracepcijsko metodo (npr. kondom ali diafragmo).
The active substance is cabozantinib (S)-malate. 
Zdravilna učinkovina je kabozantinib (S)-malat.
Black iron oxide (E172) (20 mg capsules only) Red iron oxide (E172) (80 mg capsules only) Titanium dioxide (E171) 
Ovojnica kapsule želatina črni železov oksid (E172) (samo 20 mg kapsule) rdeči železov oksid (E172) (samo 80 mg kapsule) titanov dioksid (E171)
Cabozantinib should be discontinued in patients with wound healing complications requiring medical intervention. 
Kabozantinib je treba ukiniti pri bolnikih z zapleti s celjenjem rane, zaradi katerih je potrebna zdravniška pomoč.
When using cabozantinib, periodic monitoring with on-treatment ECGs and electrolytes (serum calcium, potassium, and magnesium) should be considered. 
Pri uporabi kabozantiniba je treba razmisliti o periodičnem spremljanju EKG in elektrolitov (kalcij, kalij in magnezij v serumu) med zdravljenjem.
NOAEL for embryo-foetal toxicity and teratogenic findings were below human clinical exposure levels at intended therapeutic dose. 
NOAEL za toksičnost embria-zarodka in izsledki o teratogenosti so bili pod ravnmi klinične izpostavljenosti pri ljudeh pri nameravanih terapevtskih odmerkih.
• Lightening of skin, flakey skin, unusual pale skin 
• posvetlitev kože, luščenje kože, neobičajno bleda koža
PVC/PE/PCTFE-Al blisters with foil backing, sealed into a secondary heat-sealed card packaging. 
Pretisni omot iz PVC/PE/PCTFE-aluminija s prekrivno folijo, toplotno zavarjen v sekundarno, ovojnino, v obliki zgibanke.
Efficacy with cabozantinib was observed in medullary thyroid cancer patients with wild-type or mutant RET. 
Učinkovitost s kabozantinibom so opazili pri bolnikih z medularnim rakom ščitnice z nemutiranim ali mutiranim RET.
When PPES is severe, interruption of treatment with cabozantinib should be considered. 
Pri resni PPES je treba razmisliti o prekinitvi zdravljenja s kabozantinibom.
BATCH NUMBER<, DONATION AND PRODUCT CODES> Lot 
ŠTEVILKA SERIJE <, ENOTNE OZNAKE DAROVANJA IN IZDELKOV> Serija
Concomitant medicinal products that are strong inhibitors of CYP3A4 should be used with caution, and chronic use of concomitant medicinal products that are strong inducers of CYP3A4 should be avoided (see sections 4.4 and 4.5). 
Pri sočasni uporabi z drugimi zdravili, ki so močni zaviralci CYP3A4, je potrebna previdnost, kronični uporabi z zdravili, ki so močni induktorji CYP3A4, pa se je treba izogniti (glejte poglavji 4.4 in 4.5).
Psychiatric disorders anxiety, depression, confusional state abnormal dreams, delirium 
Psihiatrične motnje anksioznost, depresija, stanje zmedenosti nenormalne sanje, delirij
The ORR was 27.9% and 0% for subjects in the cabozantinib arm and placebo arm, respectively (p<0.0001; Table 2). 
ORR je bil 27,9 % za osebe v skupini s kabozantinibom in 0 % za osebe v skupini s placebom (p < 0,0001; preglednica 2).
Protein binding was not altered in subjects with mild or moderately impaired renal or hepatic function. 
Vezava na beljakovine ni bila spremenjena pri osebah z blago ali zmerno okvarjenim delovanjem ledvic ali jeter.
• Blood clots in the veins and the lungs 
• krvni strdki v žilah in pljučih
There is limited data in patients with cardiac impairment. 
Bolniki s srčno okvaro Podatki pri bolnikih s srčno okvaro je malo.
Do not use this medicine after the expiry date which is stated on the blister card after EXP. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na pretisni zgibanki poleg oznake EXP. Rok uporabnosti zdravila se izteče na zadnji dan navedenega meseca.
Cabozantinib should be used with caution in patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. 
Pri uporabi kabozantiniba pri bolnikih s podaljšanjem intervala QT v anamnezi, pri bolnikih, ki jemljejo antiaritmike ali pri bolnikih z relevantno obstoječo boleznijo srca, bradikardijo ali motnjo elektrolitov, je potrebna previdnost.
Depending on the dose you were prescribed, the number of capsules to take are as follows: 
Število kapsul, ki jih morate vzeti, je odvisno od odmerka, ki vam je bil predpisan, in je lahko:
Patients with severe hepatic impairment have not been studied. 
Bolnikov s hudo okvaro jeter niso preučevali.
In rabbits, cabozantinib produced foetal soft tissue changes (reduced spleen size, small or missing intermediate lung lobe) and increased foetal incidence of total malformations. 
Pri kuncih je kabozantinib povzročil spremembe mehkega tkiva pri plodu (zmanjšano velikost vranice, majhen ali manjkajoč vmesni pljučni lobus) in večjo incidenco skupnih malformacij pri plodu.
• Stopping menstruation, vaginal bleeding 
• prenehanje menstruacij, krvavitve iz nožnice
Patients who have evidence of involvement of the trachea or bronchi by tumour or a history of haemoptysis prior to treatment initiation should be carefully evaluated before initiating cabozantinib therapy. 
Bolnike, ki imajo znake vpletenosti požiralnika ali sapnic v tumor ali hemoptizo v anamnezi, je treba pred uvedbo zdravljenja s kabozantinibom skrbno oceniti.
Median Progression-Free Survival 
Mediano preživetje brez napredovanja bolezni
If you get side effects, your doctor may tell you to take COMETRIQ at a lower dose. 
Če boste dobili neželene učinke, vam bo zdravnik morda naročil, da jemljete manjše odmerke zdravila COMETRIQ.
If your next dose is due in less than 12 hours then do not take the dose that you have missed. 
Če je do naslednjega odmerka manj kot 12 ur, ne vzemite izpuščenega odmerka.